Association Between Serum Microcystins Levels and Chronic Pelvic Inflammatory Disease: a Case-control Study
Abstract Microcystins(MCs) have been reported to be closely related to the occurrence and development of inflammation by animal and cell experiments, but there are no study on the relationship between serum microcystin-LR(MC-LR) and chronic pelvic inflammatory disease (CPID) risk in populations. We designed a clinical case-control study to investigate the relationship between serum MC-LR and CPID risk. From October 2020 to March 2021, 50 patients diagnosed with CPID and 50 controls (frequency matched by age) were recruited from the First Hospital University of South China, in Hengyang, Central China. The basic information on lifestyle and history of disease was acquired through questionnaires. Blood samples were analyzed for MC-LR by ELISA. Binary logistic regression analyses and chi-square test were used to evaluate the effects of MC-LR on CPID risk. With the increase of serum MC-LR level (Q2, Q3 and Q4), the AOR of CPID risk increased (0.139, 0.167 and 0.040, respectively). The serum MC-LR(0.06 ~ 0.66µg/L) was an independent protective factor for CPID in humans, and the protective effect of concentrations ≥ 0.25μg/L was more obvious. Within the certain concentration range, MC-LR was an independent protective factor for the risk of CPID in humans, which will provide a scientific basis for the study of the relationship between serum microcystins and inflammation.